Matthias Gromeier, MD

Professor of Neurosurgery
Professor in Molecular Genetics and Microbiology
Professor in Medicine
Member of the Duke Cancer Institute
Campus mail Box 3020 Med Ctr, Durham, NC 27710
Phone (919) 668-6205
Email address grome001@mc.duke.edu

I am a classically trained virologist with a focus on molecular mechanisms of RNA virus pathogenesis. My career is dedicated to unraveling RNA virus:host relations and devising methods of exploiting them for cancer immunotherapy and vaccine design. My background is in translation regulation and mRNA metabolism, viral RNA sensing and innate immunity, and cancer immunology and immunotherapy. Basic mechanistic research in my laboratory is supporting an ambitious clinical translational research program with active multi-center clinical trials in several cancer indications. 

Education and Training

  • Postdoctoral Associate, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1996 - 1999
  • Postdoctoral fellow, Molecular Genetics & Microbiology, State University of New York, Stony Brook, 1993 - 1996
  • M.D., University of Hamburg (Germany), 1992

Publications

Mosaheb, Mubeen M., Michael C. Brown, Elena Y. Dobrikova, Mikhail I. Dobrikov, and Matthias Gromeier. “Harnessing virus tropism for dendritic cells for vaccine design.” Curr Opin Virol 44 (August 6, 2020): 73–80. https://doi.org/10.1016/j.coviro.2020.07.012.

PMID
32771959
Full Text

Kastan, Jonathan P., Elena Y. Dobrikova, Jeffrey D. Bryant, and Matthias Gromeier. “CReP mediates selective translation initiation at the endoplasmic reticulum.” Sci Adv 6, no. 23 (June 2020): eaba0745. https://doi.org/10.1126/sciadv.aba0745.

PMID
32537501
Full Text

Thompson, Eric M., Eric Thompson, Wafa Hassen, Meredith McDonald, Daniel Picard, Michael Brown, Elena Dobrikova, and Matthias Gromeier. “Poliovirus Oncolytic Activity in Medulloblastoma is Mediated by Oxidative Stress.” In Journal of Neurosurgery, 132:115–115. AMER ASSOC NEUROLOGICAL SURGEONS, 2020.

Scholars@Duke

Farrow, N. E., G. M. Beasley, A. S. MacLeod, M. A. Sarah, A. Cognetta, M. Gromeier, M. A. Selim, D. D. Bigner, R. McLendon, and M. J. Whitley. “Expression of CD155, PD-1 and PD-L1 in Non-Melanoma Skin Cancer: Implications for Treatment of Advanced Disease.” In Annals of Surgical Oncology, 27:S204–S204. SPRINGER, 2020.

Scholars@Duke

Landa, K., V. Chandramohan, M. Gonen, J. M. Winter, M. Lidsky, K. Shah, S. Zani, et al. “CD226 Expression is Associated with Increased Survival in Pancreatic Cancer.” In Annals of Surgical Oncology, 27:S128–S128. SPRINGER, 2020.

Scholars@Duke

Mosaheb, Mubeen M., Elena Y. Dobrikova, Michael C. Brown, Yuanfan Yang, Jana Cable, Hideho Okada, Smita K. Nair, Darell D. Bigner, David M. Ashley, and Matthias Gromeier. “Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.” Nat Commun 11, no. 1 (January 27, 2020): 524. https://doi.org/10.1038/s41467-019-13939-z.

PMID
31988324
Full Text

Gromeier, Matthias, Mubeen Mosaheb, Elena Dobrikova, Michael Brown, Darell Bigner, and David Ashley. “GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY.” In Neuro Oncology, 21:93–93. OXFORD UNIV PRESS INC, 2019.

Scholars@Duke

Bowie, Michelle, Seethalakshmi Hariharan, Janell Hostettler, Kristen Roso, Yiping He, Christopher Pirozzi, Martin Roskoski, et al. “ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA.” In Neuro Oncology, 21:126–126. OXFORD UNIV PRESS INC, 2019.

Scholars@Duke

Gromeier, Matthias, Michael Brown, Nike Beuabier, Hai Yan, Yiping He, Gao Zhang, Annick Desjardins, et al. “TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES.” In Neuro Oncology, 21:7–7. OXFORD UNIV PRESS INC, 2019.

Scholars@Duke

Chandramohan, Vidyalakshmi, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, et al. “Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.” J Immunother Cancer 7, no. 1 (May 29, 2019): 142. https://doi.org/10.1186/s40425-019-0614-0.

PMID
31142380
Full Text

Pages